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CD4+CD25+FoxP3+ human regulatory TCELLS (TREG) are promising candidates for
reshaping undesired immunity/inflammation by adoptive cell transfer, yet their application
is strongly dependent on robust assays testing their functionality. Several studies along
with first clinical data indicate TREG to be auspicious to use for future cell therapies, e.g., to
induce tolerance after solid organ transplantation. To this end, TREG suppressive capacity
has to be thoroughly evaluated prior to any therapeutic application. A 7 h-protocol for
the assessment of TREG function by suppression of the early activation markers CD154
and CD69 on CD4+CD25− responder TCELLS (TRESP) upon polyclonal stimulation via
αCD3/28-coated activating microbeads has previously been published. Even though
this assay has since been applied by various groups, the protocol comes with a critical
pitfall, which is yet not corrected by the journal of its original publication. Our results
demonstrate that the observed decrease in activation marker frequency on TRESP is
due to competition for αCD3/28-coated microbeads as opposed to a TREG-attributable
effect and therefore the protocol cannot further be used as a diagnostic test to assess
suppressive TREG function.
Keywords: regulatory T cell functional assay, αCD3/28-coated microbeads, competitive CD3/CD28 binding,
nullified Treg-mediated suppression, correlation between T cell-to-αCD3/CD28-coated microbead ratio and
activation marker frequency on responder T cells
INTRODUCTION
Regulatory TCELLS (TREG) are key players in maintaining immune homeostasis, resolution of
inflammation, and self (1). Exploiting those characteristics, TREG have gained plenty of attention
as promising candidates in immunotherapeutic applications for the prevention or reshaping of
undesired immune responses such as in autoimmune diseases, chronic inflammation, and allograft
rejections. Data from clinical trials identify TREG as an encouraging cell type for use in cellular
therapy (2). By the same token, a robust protocol to assess TREG function is of utmost importance
to ensure their suppressive function prior to adoptive cell-therapeutic clinical trials, as well as for
application in basic research. So far, for assessing TREG functionality, evaluating the suppressive
capacity of TREG to inhibit the proliferation of responder TCELL (TRESP) after a 4-day co-cultivation
period has been the gold-standard protocol since a decade (3, 4). Recently, Canavan et al. (5)
and Ruitenberg et al. (6) described a rapid 7 h assay for the evaluation of TREG functionality
by assessing their suppressive capacity using upregulation of the early TCELL activation makers
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CD154 (CD40L) and CD69 on conventional CD4+CD25−
responder TCELLS (TRESP) upon CD3/28 engagement. CD3/28
stimulation is mediated by microbeads coupled with αCD3 and
αCD28 antibodies. According to these studies, TREG alleviate
CD154 and CD69 expression on TRESP in a dose-dependent
manner. Even though this assay has since been frequently applied
and cited more than 80 times (7, 8, 10), we observed that the
protocol comes with a critical pitfall: TRESP and TREG both
express the signaling molecule CD3 and TCELL co-stimulatory
receptor CD28 on the plasma membrane, potentially competing
for binding αCD3/28 TCELL activating microbeads applied in
the rapid 7 h assay. We investigated whether the observed
decreased frequencies of activated TRESP can be claimed to
be a TREG-attributable effect or if it is rather a result of
competition for αCD3/28-coated activating microbeads. We thus
explored whether different ratios of αCD3/28 TCELL activation




The aim of this study was to investigate the influence of
αCD3/CD28-coated activating microbeads on the expression of
early activation markers CD69 and CD154, used for predicting
TREG functionality in basic and translational research. We
compared the expression of CD69 and CD154 of TRESP in TREG
co-cultures, which were either activated via αCD3/CD28-coated
microbeads adjusted to TRESP only or to the total cell number
present in one well (TRESP + TREG). To verify the integrity of
the TREG used in this study, as well as to demonstrate the TREG-
mediated suppressive function in a bead-uncompetitive setting,
TRESP proliferation suppression experiments were performed.
Cell Isolation
Peripheral blood mononuclear cells from healthy donors were
purified using Ficoll-Paque separation (Biochrom). CD4+ cells
were enriched by magnetic-activated cell sorting (Miltenyi)
according to manufacturer’s instructions (purity>90%). For
fluorescence-activated cell sorting (FACS Aria II, BD) of
CD4+CD25highCD127low TREG and CD4
+CD25− TRESP, cells
were stained with CD4 (SK3, Biolegend), CD25 (2A3, BD), and
CD127 (R34.34, Beckman Coulter). Post-FACSort analysis by
flow cytometry yielded CD25+FoxP3+ TCELL purity of >95%.
7h Diagnostic Test for TREG Function and
αCD3/28 Microbead Titration
Assays were performed as described by Canavan et al. (5). Briefly,
CFSE-labeled TRESP were co-cultured with autologous TREG at
TRESP/TREG ratios ranging from 1:1 to 32:1. In two parallel setups,
cells were either stimulated with αCD3/28-coated microbeads
(Dynabeads R© Human T-Activator CD3/CD28, Thermo Fisher
Scientific) at a bead/cell ratio of 0.2 adjusted to the TRESP cell
number per well (5, 6) or adapting the ratio of 0.2 to the total cell
number per well including TREG. Stimulated and unstimulated
TRESP without TREG were included as controls. For themicrobead
titration, TRESP were cultured alone at bead/TRESP ratios ranging
from 0.1 to 0.4 (mimicking the presence of TREG). αCD154 (24–
31) was added at start of incubation. Cells were incubated at 37◦C
for 7 h. All cell cultures were performed in X-Vivo-15 medium
supplemented with 10% FCS (Lonza & Biochrom) and 100 IU/ml
Penicillin/Streptomycin. After harvesting, cells were stained with
CD3 (OKT3), CD4 (SK3), CD137 (4B4-4), and CD69 (FN50),
all Biolegend. Dead cells were excluded (LIFE/DEADTM Fixable
Blue Dead Cell Stain Kit, Thermo Fisher Scientific).
Proliferation Suppression Assay
CFSE-labeled TRESP were cultured alone or with autologous
TREGS at TRESP/TREG ratios ranging from 1:1 to 16:1. The
cells were stimulated with αCD3/28-coated microbeads (TREG
Suppression Inspector, Miltenyi) at a cell/bead ratio of 1:1 and
1:2 adjusted to the total cell number per well and incubated at
37◦C for 96 h. Thereafter, cells were stained with CD3 (OKT3),
CD4 (SK3), all Biolegend. Dead cells were excluded (Thermo
Fisher Scientific). Proliferation was assessed by CFSE dilution
and percentage suppression of proliferation was calculated by
relating the percentage of proliferating TRESP in the presence and
absence of TREG, respectively.
Flow Cytometry Analysis
Data were acquired on a LSR-II Fortessa flow cytometer (BD) and
analyzed using FlowJo V10 (TreeStar).
Statistics
Analysis was performed with GraphPad Prism software (version
6, GraphPad, La Jolla, CA) and R (version 3.4.1) (9). We
have tested for significant interaction, i.e., non-parallel response
profiles of the two bead adjustment methods to the different
TRESP:TREG ratios, using a non-parametric rank-based ANOVA-
type statistic [as implemented in the nparLD package (11)] in a
two-way factorial repeated measures design. For bead titration
experiments, non-parametric two-tailed Wilcoxon matched-
pairs signed rank tests were used to determine significance in
pairwise comparison. Data indicate means ± SEMs in all bar
graphs. P < 0.05 was considered significant.
RESULTS
TCELL Early Activation Marker Expression
Is Dependent of TCR Engagement
We first examined TREG functionality according to the protocols
published by Canavan et al. (5) and Ruitenberg et al. (6),
whereby ex vivo FACSorted and CFSE-labeled TRESP were co-
cultured in the presence and absence of autologous TREG and
stimulated with αCD3/28-coated activating microbeads at a
ratio of 0.2 microbeads per TRESP (Figure 1A). After 7 h, the
mean frequency of CD154+ and CD69+ TCELLS of unstimulated
TRESP was 0.14 and 0.45%, respectively and 57.25 and 78.26%
on CD3/28-stimulated TRESP, respectively (Figure 1B). When
TRESP were stimulated in the presence of TREG at ratio 1:1,
the mean frequency of CD154+ and CD69+ TCELLS decreased
to 47.77 and 69.86%, respectively. With increasing TRESP/TREG
ratios both, CD154 and CD69 expression, increased in a linear
fashion (Figure 1C, quantified in E, F, red columns). We
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FIGURE 1 | TCELL early activation marker expression is dependent of TCR engagement and cannot be used for TREG functional evaluation. FACSorted CD4
+CD25−
TRESP with and without autologous TREG co-culture were stimulated with anti-CD3/CD28-coated microbeads and analyzed for early activation marker expression.
(A) For precise TRESP/TREG discrimination, TRESP were labeled with CFDA-SE (CFSE). (B) Representative plots of CD154 and CD69 expression on unstimulated and
stimulated TRESP cultured without TREG. (C) Representative plots of CD154 and CD69 expression of TRESP co-cultured with TREG at different TRESP:TREG ratios and
stimulated with anti-CD3/CD28-coated microbeads adjusted to TRESP. (D) Representative plots of CD154 and CD69 expression of TRESP co-cultured with TREG at
different TRESP:TREG ratios and stimulated with anti-CD3/CD28-coated microbeads adjusted to total cell number. (E,F) Quantified data from (C,D), respectively.
CD154 and CD69 of CFSE+TRESP co-cultured with FACSorted TREG at different TRESP:TREG ratios and stimulated with anti-CD3/CD28-coated microbeads
adjusted to TRESP (red columns) and to total cell numbers (blue columns). For clarification, the table summarizes the experimental setups. n = 7. Non-parametric
rank-based ANOVA-type statistic **p < 0.001 (CD154: p = 1.90E-06, CD69: p = 5.527256E-16). (G) Expression of CD154 and (H) expression of CD69 of
CFSE+TRESP co-cultured with FACSorted TNON−TREG at different TRESP:TREG ratios and stimulated with anti-CD3/CD28-coated microbeads adjusted to TRESP
(red columns) and to total cell numbers (blue columns). n = 3. (I) Expression of CD154 and (J) expression of CD69 of CFSE+TRESP after different
anti-CD3/CD28-coated microbead:TRESP ratio stimulation. For clarification, the table summarizes the experimental setups. n = 7. *p < 0.05, Wilcoxon matched-pairs
signed rank test. TRESP:TREG/TNON−TREG co-cultures (E,F) and corresponding bead titration (I,J) experiments were performed simultaneously using the same donor
cells. Median data of independent experiments are shown and error bars represent SEM.
next determined whether the total TCELL/bead ratio influences
TREG-induced activation marker suppression. Accordingly, we
adjusted the bead numbers to the total cell numbers, including
TREG, thereby eluding the bead competition in contrast to
Canavan et al. (5) and Ruitenberg et al. (6). In that case,
TRESP activation in the presence of TREG equaled control TRESP
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FIGURE 2 | Ex vivo isolated TREG demonstrate a dose-dependent TRESP proliferation suppression in a bead-uncompetitive setting. FACSorted CFSE
+CD4+CD25−
TRESP were co-cultured with autologous FACSorted TREG and stimulated with anti-CD3/CD28-coated microbeads for 96 h. TRESP proliferation was analyzed by
CFSE dilution. Representative plots depicting (A) CFSE-labeling strategy to accurately analyze TRESP proliferation; (B) proliferation of unstimulated and stimulated
CFSE+TRESP cultured without TREG and (C) CFSE
+TRESP proliferation after co-culture with different TREG ratios. (D) Percentage of TRESP proliferation after
co-culture with decreasing TRESP:TREG ratios (green bars) and TRESP:TNON-TREG ratios (blue bars) stimulated with a total cell number:bead ratio of 1:1. n = 7
TRESP:TREG co-cultures, n = 3 TRESP:TNON−TREG co-cultures. (E) Percentage of TRESP proliferation after co-culture with decreasing TRESP:TREG ratios (green bars)
and TRESP:TNON-TREG ratios (blue bars) stimulated with a total cell number:bead ratio of 1:2. n = 3. Median data of independent experiments are shown and error
bars represent SEM.
cultures without TREG (Figure 1D, quantified in E, F, blue bars),
indicating that indeed TRESP and TREG compete for CD3/28-
binding microbeads. Serving as a negative control, we co-
cultured TRESP with CD4
+CD25− non-TREG/effector TCELLS
in place of TREG. When the bead number was adjusted to
TRESP only we observed similar reductions of CD154 and CD69
expression (Figures 1G,H, red bars) as when TRESP were co-
cultured with TREG (Figures 1E,F, red bars). Correspondingly,
when adjusting the bead number to the total cell number
(Figures 1E,H, blue bars), the expression of CD154 and CD69 is
similar to the conditions with TRESP only (Figures 1E–H, gray
bars). To mimic the competition for the activating microbead
stimuli, we stimulated TRESP with different amounts of αCD3/28-
coated microbeads in the absence of TREG. We set the actual
bead/TCELL ratio according to the published TRESP/TREG co-
culture approach, in which the activation bead/TRESP ratio is
adjusted to TRESP only, i.e., calculated the actual bead/TCELL
ratio in each setting. CD154 and CD69 expression decreased
in a dose-dependent manner with highest expression levels at
a bead/TRESP ratio of 0.4 (69.83 and 89.47%, respectively) and
lowest at a ratio of 0.1 (37.80 and 53.33%, respectively). The
TRESP activation pattern with the different bead ratios ranging
from 0.1 to 0.194 indicate a strong bead/TRESP ratio dependency
(Figures 1I,J).
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TREG Demonstrate a Dose-Dependent
TRESP Proliferation Suppression in a
Bead-Uncompetitive Setting
To confirm TREG functionality in an environment where
the number of αCD3/28-activation microbeads is adjusted to
the total cell number, the gold-standard TRESP proliferation
suppression assay was performed. The proliferation assay
was conducted with TCELLS of the same donors in parallel
to the experiments shown in Figure 1. Following activation,
TRESP proliferation alone yielded 52.03% and dose-dependently
decreased in the presence of TREG to 15.51% at a TRESP/TREG
ratio of 1:1 (Figures 2A–C, quantified in Figure 2D, green bars).
Thus, we conclude that the TREG employed in this study are
able to suppress TRESP proliferation in a standardized bead-
competitive setting. To ascertain the reduction of proliferation
to be TREG-mediated, we have added non-TREG/effector TCELLS
instead of TREG to TRESP and observed no decrease in TRESP
proliferation, indicating the suppression of TRESP proliferation
to be a TREG-attributable effect (Figure 2D, blue bars). Even
when TCELLS are stimulated with twice the number of
activating αCD3/CD28 microbeads, the TREG-specific impact in
suppressing TRESP proliferation can be seen (Figure 2E).
DISCUSSION
In conclusion, when adjusting the αCD3/28-bead numbers
to only TRESP in co-cultures of TRESP and TREG, activation
marker expression was comparable to approaches where TRESP
were cultured alone at same bead/total cell ratio present in
the TRESP/TREG co-culture. When normalizing αCD3/28-bead
competition by adjusting the bead number to total cell numbers,
TREG-mediated suppression of activation marker upregulation is
nullified. Even more strikingly, when titrating non-TREG/effector
TCELLS to TRESP and adjusting the αCD3/28-bead numbers
to TRESP only, we observe the same decrease in activation
marker expression as in TRESP:TREG co-cultures. We thereby
demonstrate that the suppression of activationmarker expression
on TRESP observed in co-cultures with TREG are due to
competitive TCELL receptor and CD28 engagement limited by
αCD3/28 microbead availability rather than by suppressive
activity of TREG (Supplementary Figure 1). There is a pressing
demand for a fast assay to evaluate TREG functionality, especially
in the light of upcoming clinical trials needing a robust diagnostic
test to assess the suppressive function as a release criterion for
their TREG cell products. Nonetheless, the TRESP proliferation
suppression analysis should still be considered as the gold-
standard TREG functional assay as it is performed by adjusting
the activation bead to TCELL ratios in experimental setups with
decreasing TREG cell numbers (to assess TREG dose-dependent
suppression). Since we firmly believe that activation bead to
TCELL receptor competition should be kept constant throughout
all conditions within a TREG functional assay, we claim that
the rapid assessment for human TREG function proposed by
Canavan et al. (5) and Ruitenberg et al. (6) does not result in
reliable evidence of functional suppression since the putative
TREG-mediated suppression of TRESP activation is to be ascribed
to competitive TCELL receptor and CD28 engagement. Hence, we
suggest that the previously published protocol is unsuitable as a
diagnostic test to assess suppressive TREG function.
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